In a randomized study, patients aged 12 years or older with acne vulgaris were assigned to receive either twice-daily treatment of their whole face with a 1% clascoterone cream—a topical androgen receptor inhibitor—or vehicle. After 12 weeks of treatment, patients who used the cream had less inflammatory, noninflammatory, and total lesions than patients who used the vehicle, and more patients who used the cream were deemed to have achieved “treatment success” (19.9%) than patients who used the vehicle (7.7%). Low rates of local skin reactions were reported in the group of patients using the cream. The study authors concluded, “Clascoterone is efficacious, with a favorable safety profile and low rates of local skin reactions in patients ≥ 12 years of age with facial acne vulgaris.” These findings were published by Hebert et al in the Journal of Drugs in Dermatology.
June 08, 2023